[1] Delic S,Rose D,Kern W,et al.Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia,primary myelofibrosis and polycythaemia vera[J].Br Haematol,2016,175(3):419~426. [2] Bertozzi I,Peroni E,Coltro G,et al.Thrombotic risk correlates with mutational status in true essential thrombocythemia[J].Eur Clin Invest,2016,46(8):683~689. [3] Birgegrd G.The use of anagrelide in myeloproliferative neoplasms,with focus on essential thrombocythemia[J].Curr Hematol Malig Rep,2016,11(5):348~355. [4] 安冬颖.干扰素与高三尖杉酯碱联合应用方案治疗原发性血小板增多症的临床效果观察[J].中国现代药物应用,2016,10(1):191~192. [5] Cavalca V,Rocca B,Squellerio I,et al.In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia[J].Thromb Haemost,2014,112(1):118~127. [6] 张之南,沈悌.血液病诊断标准及疗效标准[M].第3版。北京:科学出版社,2011. [7] 郭子文,许晓军,周云香.羟基脲加干扰素治疗原发性血小板增多症的临床疗效研究[J].现代诊断与治疗,2015,26(11):2477~2478. [8] Shrestha R,Giri S,Pathak R,et al.Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia[J].World Clin Oncol,2016,7(4):324~330. [9] Sun C,Zhou X,Zou ZJ,et al.Clinical manifestation of calreticulin gene mutations in essential thrombocythemia without janus kinase 2 and MPL mutations:a Chinese cohort clinical study[J].Chin Med (Engl),2016,129(15):1778~1783. [10] 江燕,杨思进,白雪,等.原发性血小板增多症致急性心肌梗死1例治疗体会[J].临床心血管病杂志,2016,32(1):105~107. [11] Ferdowsi S,Ghaffari SH,Amirizadeh N,et al.JAK2V617F allele burden measurement in peripheral blood of iranian patients with myeloproliferative neoplasms and effect of hydroxyurea on JAK2V617F allele burden[J].Int Hematol Oncol Stem Cell Res,2016,10(2):70~78. [12] 安冬颖.羟基脲与干扰素联合方案治疗原发性血小板增多症的临床疗效观察[J].中国现代药物应用,2015,9(22):116~117. [13] Tefferi A,Barbui T.Polycythemia vera and essential thrombocythemia:2015 update on diagnosis,risk-stratification and management[J].Am Hematol,2015,90(2):162~173.
2017, Vol. 23 
冀公网安备13080202000677号